Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

PARN Inhibitors

PARN inhibitors represent a distinctive class of chemical compounds that exhibit a specific mode of action targeting a fundamental cellular process. These inhibitors are meticulously designed to interact with and modulate the activity of poly(A)-specific ribonuclease (PARN), an enzyme that plays a pivotal role in RNA degradation within cells. RNA degradation is a tightly regulated process that governs the lifespan of various RNA molecules, particularly messenger RNAs (mRNAs) which serve as templates for protein synthesis. The enzymatic function of PARN revolves around the hydrolytic cleavage of the poly(A) tail, a string of adenine nucleotides at the 3' end of mRNAs. This cleavage leads to the shortening of the poly(A) tail and, consequently, hastens the decay of the mRNA molecule. PARN inhibitors are engineered to interact with the catalytic site of the PARN enzyme, thereby disrupting its intrinsic ribonucleolytic activity.

By obstructing this enzymatic activity, PARN inhibitors can potentially impede the degradation of mRNAs, resulting in the accumulation of mRNAs with extended poly(A) tails. This altered RNA degradation landscape could have cascading effects on gene expression patterns, as the stability of mRNAs influences their translation into proteins. The modulation of PARN's activity by these inhibitors can thus indirectly influence cellular processes that hinge on precise gene expression regulation. Research and exploration into PARN inhibitors offer a multifaceted insight into the intricate realm of RNA metabolism and post-transcriptional gene regulation. By unraveling the molecular intricacies of PARN inhibition, scientists gain a deeper comprehension of how cells orchestrate the lifespan of RNA molecules, ultimately sculpting the cellular proteome. While the implications of PARN inhibitors extend beyond the scope of their potential applications, the study of these compounds offers a unique avenue for deciphering the mechanisms governing RNA degradation dynamics and gene expression control.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$210.00
$305.00
$495.00
10
(1)

Used for ovarian cancer and specific types of breast cancer linked to BRCA mutations.

Rucaparib

283173-50-2sc-507419
5 mg
$150.00
(0)

Approved for ovarian cancer and certain other solid tumors with specific genetic mutations.

Niraparib

1038915-60-4sc-507492
10 mg
$150.00
(0)

Used as maintenance therapy for recurrent ovarian cancer that responds to platinum-based chemotherapy.

Veliparib

912444-00-9sc-394457A
sc-394457
sc-394457B
5 mg
10 mg
50 mg
$182.00
$275.00
$726.00
3
(0)

Studied in combination with chemotherapy and radiation therapy for various cancers.